Recent IMMP News
- Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Immutep Quarterly Activities Report Q3 FY24 • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Immutep Announces First Clinical Data from 90mg Dosing of Efti • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 09:01:56 PM
- Immutep Quarterly Activities Report Q2 FY24 • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 11:06:56 AM
- Immutep Receives A$2.6 million R&D Tax Incentive from French Government • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial • GlobeNewswire Inc. • 11/22/2023 01:00:00 PM
- Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer • GlobeNewswire Inc. • 11/06/2023 01:00:00 PM
- Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 10:06:58 AM
- Immutep to Participate in November Investor Events • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Immutep Quarterly Activities Report Q1 FY24 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Immutep receives ~A$1.13 million R&D Tax Incentive • GlobeNewswire Inc. • 10/25/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/25/2023 10:07:25 AM
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/24/2023 10:35:30 AM
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- Immutep Announces Publication of Abstracts at ESMO Congress 2023 • GlobeNewswire Inc. • 10/16/2023 12:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM